Barclays initiated coverage of four small- and mid-cap biotech firms with Overweight ratings.
Analyst Lukas Shumway noted that differentiated platforms with sound science and prior data shift risk-reward favorably.
Sutro Biopharma and Immunome operate in the antibody-drug conjugate (ADC) space, which has attracted over $125 billion since 2019.
Immunomedics nears its first commercial approval, while Sutro's cell-free platform improves safety and efficacy.
Cellectis brings an allogeneic CAR-T platform, positioning alongside established autologous players with potential solid tumor expansion.
Alpha Tau Medical's Alpha DaRT implant triggers immune responses, offering tumor-agnostic potential.
